Promising combo for blood cancer shows early success in small study
NCT ID NCT03623373
First seen Apr 02, 2026 · Last updated May 19, 2026 · Updated 6 times
Summary
This study tested a combination of the targeted drug acalabrutinib with chemotherapy in 13 people newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal was to see if the treatment is safe and helps collect stem cells for a future transplant. Results suggest the approach may improve response rates before transplant, but long-term disease control still requires ongoing management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.